This study investigated the antibody responses induced by the BNT162b2 mRNA COVID-19 vaccine against three SARS-CoV-2 variants: the D614G substitution variant, the B.1.1.7 variant, and the B.1.351 variant. Sera from 180 vaccinated healthcare workers were analyzed. The vaccine effectively neutralized the D614G and B.1.1.7 variants, while neutralization of the B.1.351 variant was reduced five-fold. Despite this reduction, 92% of vaccinated individuals still showed a neutralization titer >20 against B.1.351, suggesting some level of protection. The vaccinees' neutralization titers were higher than those observed in recovered COVID-19 patients.

Pinja Jalkanen, Pekka Kolehmainen, Hanni K. Häkkinen, Moona Huttunen, Paula A. Tähti nen, Rickard Lundberg, Sari Maljanen, Arttu Reinholm, Sisko Taurij ainen, Sari H. Pakkanen, Iris Levonen, Arttu Nousiainen, Taru Miller, Hanna Välimaa, Lauri Ivaska, Arja Pasternack, Rauno Naves, Olli Ritvos, Pamela Österlund, Suvi Kuivanen, Teemu Smura, Jussi Hepojoki, Olli Vapalahti, Johanna Lempainen, Laura Kakkola, Anu Kantele, Ilkka Julkunen